A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

The sodium –glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascu...

Source: Cardiovascular Diabetology - February 23, 2017 Category: Cardiology Authors: Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V. Karg, Peter Bramlage and Roland E. Schmieder Source Type: research